Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.52 |
| ▸ | PPARG | P37231 | 4/20 | 0.52 |
| ▸ | LDHA | P00338 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 3/20 | 0.45 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.45 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | BMP1 | P13497 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5751165 | 0.88 | PPARG (0.54) | EPHX2PPARGPPARA | |
| SCHEMBL5751205 | 0.88 | PPARG (0.54) | EPHX2PPARGPPARA | |
| SCHEMBL5753961 | 0.87 | MAPK14 (0.55) | EPHX2PPARGMAOBPPARAPPARD | |
| SCHEMBL5753587 | 0.87 | PPARG (0.53) | EPHX2PPARGPPARAFFAR1 | |
| SCHEMBL5752926 | 0.86 | LDHA (0.52) | EPHX2PPARGLDHAPPARAALDH1A1 | |
| SCHEMBL5752412 | 0.86 | PPARG (0.52) | EPHX2PPARGPPARAALDH1A1MEN1 | |
| SCHEMBL5750614 | 0.85 | PPARG (0.51) | EPHX2PPARGMAOBPPARAMEN1 | |
| SCHEMBL27429943 | 0.84 | LDHA (0.59) | EPHX2PPARGLDHAPPARAALDH1A1 | |
| SCHEMBL27686858 | 0.83 | PPARG (0.57) | EPHX2PPARGPPARAALDH1A1MEN1 | |
| SCHEMBL5750586 | 0.82 | PPARG (0.51) | EPHX2PPARGPPARAPPARDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | EPHX2 1434/4885PPARG 905/4885LDHA 3190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.